A Phase 2, Open-label Study to Evaluate the Safety, Efficacy, Dosing, and Timing of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent for the Intraoperative Identification of Lung Cancer
Latest Information Update: 25 Oct 2023
At a glance
- Drugs VGT 309 (Primary)
- Indications Lung cancer; Non-small cell lung cancer
- Focus Adverse reactions; Diagnostic use
- Sponsors Vergent Bioscience
- 12 Sep 2023 Results assessing safety, efficacy, dosing, and timing of VGT-309, presented at the 24th World Conference on Lung Cancer.
- 27 Oct 2021 Planned End Date changed from 30 Sep 2021 to 30 Dec 2021.
- 27 Oct 2021 Planned initiation date changed from 1 Apr 2021 to 11 May 2021.